<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.3 20210610//EN" "https://jats.nlm.nih.gov/publishing/1.3/JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">IPJ</journal-id>
      <journal-title-group>
        <journal-title>International Physiology Journal</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2578-8590</issn>
      <publisher>
        <publisher-name>Open Access Pub</publisher-name>
        <publisher-loc>United States</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">IPJ-18-2113</article-id>
      <article-id pub-id-type="doi">10.14302/issn.2578-8590.ipj-18-2113</article-id>
      <article-categories>
        <subj-group>
          <subject>research-article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Profile of Similarity of Electron Withdrawing Structure Towards Analgesic-Anti-Inflammatory Activity of The Novel Isatin Analogue: Design and Implementation of Phase I Drug Discovery</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Rahul</surname>
            <given-names>Hajare</given-names>
          </name>
          <xref ref-type="aff" rid="idm1849623260">1</xref>
          <xref ref-type="aff" rid="idm1849622252">*</xref>
        </contrib>
      </contrib-group>
      <aff id="idm1849623260">
        <label>1</label>
        <addr-line>Indian Council of Medical Research, New Delhi</addr-line>
      </aff>
      <aff id="idm1849622252">
        <label>*</label>
        <addr-line>corresponding author</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Nasim</surname>
            <given-names>Habibzadeh</given-names>
          </name>
          <xref ref-type="aff" rid="idm1849739396">1</xref>
        </contrib>
      </contrib-group>
      <aff id="idm1849739396">
        <label>1</label>
        <addr-line>Teesside university </addr-line>
      </aff>
      <author-notes>
        <corresp>
    
    Rahul Hajare , <addr-line>Indian Council of Medical Research, New Delhi</addr-line>, Email:  <email>rahulhajare@rediffmail.com</email></corresp>
        <fn fn-type="conflict" id="idm1841805316">
          <p>The authors have declared that no competing interests exist.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub" iso-8601-date="2018-05-14">
        <day>14</day>
        <month>05</month>
        <year>2018</year>
      </pub-date>
      <volume>1</volume>
      <issue>2</issue>
      <fpage>7</fpage>
      <lpage>14</lpage>
      <history>
        <date date-type="received">
          <day>03</day>
          <month>05</month>
          <year>2018</year>
        </date>
        <date date-type="accepted">
          <day>03</day>
          <month>05</month>
          <year>2018</year>
        </date>
        <date date-type="online">
          <day>14</day>
          <month>05</month>
          <year>2018</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© </copyright-statement>
        <copyright-year>2018</copyright-year>
        <copyright-holder>Rahul Hajare. et al.</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://openaccesspub.org/ipj/article/748">This article is available from http://openaccesspub.org/ipj/article/748</self-uri>
      <abstract>
        <p>Isatin (1H-indole-2,3-dione ) and derivatives demonstrate a diverse array of biological activities. Isatin and 5-halo derivatives have reacted to form the schiff’s bases , mannich bases and Friedel-Crafts alkylation’s to form C-C, C-N, C=N bonds. From the spectral studies, isatin has undergone reaction at C-3 and N-1 position and synthesized lead in present scheme and seen the similarity of structure and analgesic-anti-inflammatory activity.</p>
      </abstract>
      <kwd-group>
        <kwd>Schiff’s base</kwd>
        <kwd>n-benzylation</kwd>
        <kwd>dimethylformamide</kwd>
        <kwd>anti-inflammatory</kwd>
        <kwd>analgesic.</kwd>
      </kwd-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="4"/>
        <page-count count="8"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="idm1849483316" sec-type="intro">
      <title>Introduction</title>
      <p>Isatin is a versatile compound isolated in 1988 and reported to possess a wide range of biological activity in mammals. Isatin also is a synthetically versatile substrate that can be used to prepare a large variety of heterocyclic compounds, such as indoles and quinolines, and as a raw material for drug synthesis. Schiff bases and mannich bases of isatin are known to possess a wide range of pharmacological properties including anticonvulsant, antibacterial, antiprotozoal, antifungal, antiviral, anti-HIV, tuberculostatic, analgesic, anticancer activities. In the view of this fact, we have planned the synthesis of some novel isatin analogues and screening them for analgesic-anti-inflammatory activity. Isatin, an extract from Strobilanthes cusia. The roots and the leaves of the plant, Strobilanthes cusia of the Acanthaceae family that is widely distributed in northern and central China, have been used in traditional Chinese medicine to treat a variety of ailments caused by microorganisms and viruses.</p>
      <fig><graphic xlink:href="images/image1.jpg" mime-subtype="jpg"/>
    </fig></sec>
    <sec id="idm1849482740">
      <title>Experimental:</title>
      <sec id="idm1849484900">
        <title> Material and Methods </title>
        <p>All reagents were obtained from Sigma Aldrich Bangalore, and Loba Chemie, Mumbai. All the solvents used in these studies were dried and distilled before use. Melting points were determined by open capillary tube method and are uncorrected. The purity and homogeneity of the synthesized compound were ascertained by T.L.C. on glass plate using silica gel G as adsorbent and solvent system benzene: ethanol (9:1). The spot was visualized by iodine vapor. The <sup>1</sup>H-NMR spectra were recorded on CDCl3 (BRUCKRS). All spectra were obtained from Indian Institute of Technology Pawai Mumbai. </p>
      </sec>
      <sec id="idm1849482164">
        <title>Methodology</title>
        <sec id="idm1849481732">
          <title>Scheme </title>
          <p>1] Synthesis of 5-substituted-indole-2, 3 dione (Isatin)</p>
          <fig><graphic xlink:href="images/image2.jpeg" mime-subtype="jpeg"/>
          </fig><fig><graphic xlink:href="images/image3.jpeg" mime-subtype="jpeg"/>
          </fig><p>SubstitutedIsatin                                                                 </p>
          <p>(Scheme I)</p>
          <p>2] Method of preparation of 5-substituted N-benzyl isatin derivatives</p>
          <fig><graphic xlink:href="images/image4.jpg" mime-subtype="jpg"/>
          </fig><p>Where,R<sup>1</sup>=H,Cl,F,NO<sub>2                                                           </sub></p>
          <p>(Scheme II)</p>
          <p>3] Methods of preparation of Schiff’s bases of 5-substituted N-benzyl isatin derivatives:</p>
          <fig><graphic xlink:href="images/image5.jpg" mime-subtype="jpg"/>
          </fig><fig><graphic xlink:href="images/image6.jpeg" mime-subtype="jpeg"/>
          </fig><p> (Scheme III)</p>
        </sec>
      </sec>
      <sec id="idm1849485116">
        <title>Lab Scale R &amp; D </title>
        <sec id="idm1849485404">
          <title>Methods of Preparation of 5-substituted N-benzyl isatin derivatives:<sup> 6</sup></title>
          <p>Equimolecular quantity of isatin and benzyl chloride was taken in RBF. To this mixture 20 ml of dimethyl formamide and potassium carbonate were added. After gently shaking the mixture refluxed for 2hrs. The mixture was cooled and poured into the 100 ml of ice cold water. The resultant orange colour precipitate was collected and washed with water. After drying it was recrystallized from ethanol. M.P. is120<sup>0</sup>C-130<sup>0</sup>C <xref ref-type="bibr" rid="ridm1842442716">1</xref><xref ref-type="bibr" rid="ridm1842439260">2</xref>.</p>
        </sec>
        <sec id="idm1849457556">
          <title>Methods of Preparation of Schiff’s bases of 5-substituted N-benzyl isatin derivatives:</title>
          <p>Equimolecular quantity of N-benzyl derivatives and amines was added into 20ml of absolute ethanol in 250 ml of round bottom flask. In this mixture few drops of glacial acetic acid were added. The reaction mixture was refluxed for 2-3 hour extended and checked for completion through visual procedure. After completion of reaction the mixture was placed for 24 hour, filtered and recrystallized from ethanol <xref ref-type="bibr" rid="ridm1842455404">3</xref><xref ref-type="bibr" rid="ridm1842553484">4</xref>. (<xref ref-type="table" rid="idm1842296524">Table 1</xref>)</p>
          <table-wrap id="idm1842296524">
            <label>   Table 1.</label>
            <caption>
              <title>  List of compounds</title>
            </caption>
            <table rules="all" frame="box">
              <tbody>
                <tr>
                  <th>
                    <bold>CODE</bold>
                  </th>
                  <td>
                    <bold>COMPOUND</bold>
                  </td>
                  <td>
                    <bold>TEXTURE</bold>
                  </td>
                </tr>
                <tr>
                  <td>P-01</td>
                  <td>
                    <inline-graphic xlink:href="images/image7.jpeg" mime-subtype="jpeg"/>
                  </td>
                  <td>Yellow crystalline</td>
                </tr>
                <tr>
                  <td>P-02</td>
                  <td>
                    <inline-graphic xlink:href="images/image8.jpeg" mime-subtype="jpeg"/>
                  </td>
                  <td>Orange crystalline</td>
                </tr>
                <tr>
                  <td>P-03</td>
                  <td>
                    <inline-graphic xlink:href="images/image9.jpeg" mime-subtype="jpeg"/>
                  </td>
                  <td>Yellow shiny crystalline </td>
                </tr>
                <tr>
                  <td>P-04</td>
                  <td>
                    <inline-graphic xlink:href="images/image10.jpeg" mime-subtype="jpeg"/>
                  </td>
                  <td>Orange crystalline </td>
                </tr>
                <tr>
                  <td>P-05 </td>
                  <td>
                    <inline-graphic xlink:href="images/image11.jpeg" mime-subtype="jpeg"/>
                  </td>
                  <td>Red-orange crystalline </td>
                </tr>
                <tr>
                  <td>P-06</td>
                  <td>
                    <inline-graphic xlink:href="images/image12.jpeg" mime-subtype="jpeg"/>
                  </td>
                  <td>Brown crystalline </td>
                </tr>
                <tr>
                  <td>P-07</td>
                  <td>
                    <inline-graphic xlink:href="images/image13.jpeg" mime-subtype="jpeg"/>
                  </td>
                  <td>Red orange crystal </td>
                </tr>
                <tr>
                  <td>P-08</td>
                  <td>
                    <inline-graphic xlink:href="images/image14.jpeg" mime-subtype="jpeg"/>
                  </td>
                  <td>Brown </td>
                </tr>
                <tr>
                  <td>P-09</td>
                  <td>
                    <inline-graphic xlink:href="images/image15.jpeg" mime-subtype="jpeg"/>
                  </td>
                  <td>Yellow crystalline </td>
                </tr>
                <tr>
                  <td>P-10</td>
                  <td>
                    <inline-graphic xlink:href="images/image16.jpeg" mime-subtype="jpeg"/>
                  </td>
                  <td>Yellow crystalline </td>
                </tr>
                <tr>
                  <td>P-11</td>
                  <td>
                    <inline-graphic xlink:href="images/image17.jpeg" mime-subtype="jpeg"/>
                  </td>
                  <td>Yellow crystalline </td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </sec>
      </sec>
      <sec id="idm1849418468">
        <title>Preliminary Pharmacological Screening</title>
        <sec id="idm1849420124">
          <title>Acute Toxicity Studies, Cut-off LD<sub>50</sub></title>
          <p>LD<sub>50</sub> of test compounds was performed at Anuradha College of Pharmacy Chikhali as per the O.E.C.D. guideline. Test compounds were suspended in 1% CMC solution. The compounds were administered orally at a dose level of 300,500 and 1000 mg/kg body weight, to groups of 6 animals. After administration of test compounds the rats were observed for gross behavioral neurological autonomic and toxic effects. The toxicological effects were observed in terms of mortality. No death occurred within 24 h of dose of 300 and 500mg/kg but at a dose of 1000mg/kg 50% mortality was observed. As dose has increased further up to 4000mg/kg, all the animals have died. Hence 1000 mg/kg dose was considered as LD<sub>50</sub>. 1/10<sup>th</sup> of the LD<sub>50</sub> was considered as an effective dose i.e.100 mg/kg.</p>
        </sec>
        <sec id="idm1849420412">
          <title> Evaluation of Analgesic Activity. (Writhing test)</title>
          <p>The method has followed described by International standards. The total number of writhing following intraperitoneal administration of acetic acid solution (1%, 10 ml/kg) was recorded over a period of 30 min, starting 5 min after acetic acid injection. The mice were treated with test (100 mg/kg) suspended in 1% CMC or standard drug (Aspirin, 300 mg/kg), 30 min before administration of acetic acid <xref ref-type="bibr" rid="ridm1842298204">5</xref>. </p>
          <p>The number of writhings and stretching was recorded and permitted to express the percentage of protection using the ratio = (Control mean-treated mean) ×100/control mean</p>
        </sec>
        <sec id="idm1849419332">
          <title>Carrageenan-Induced Hind Paw Edema in Rats.</title>
          <p>The acute hind paw edema was produced by injecting 0.1 ml of Carrageenan (prepared as 1% suspension in 1% CMC) locally into the plantar aponeurosis of the right hind paw of rats,  to  groups of six ,and standard drug, acetylsalicylic acid (ASA, 300 mg/kg), respectively.  Test (drug 100 mg/kg) and ASA were administered 1 h prior to the injection of Carrageenan. The rat pedal volume up to the ankle joint was measured using plethysmometer at 0 h (just before) and 1h and 3 h after the injection of Carrageenan. Increase in the paw edema volume was considered as the difference. Percent inhibition of edema volume between treated and a control group was calculated as follows:</p>
          <p>Percent inhibition = (Vc − Vt)/Vc × 100, Where Vt = mean relative change in a paw volume in test group and Vc = mean relative change in paw volume in control group.</p>
        </sec>
      </sec>
    </sec>
    <sec id="idm1849433012" sec-type="results">
      <title>Result and Discussion</title>
      <p>The all synthesized compound was analyzed by <sup>1</sup>H-NMR spectra on CDCl<sub>3.</sub>The reproducibility of the developed method was ascertained by considering the physical properties of the synthesized compound.  </p>
      <p>
        <bold>N-benzyl 3-<sup>(phenylimino)</sup>-1,3-dihydro-indole-2one (P-01)</bold>
      </p>
      <p>Yield 70%, m.p.260<sup>0</sup>C, Rf value 0.6, <sup>1</sup>H-NMR (1H) =N-NH d 12.82, (4-H) d 7.6, (2 Ar-H) N-CH<sub>2</sub> d 6.6.</p>
      <p>
        <bold>N-benzyl 3-[(2, </bold>
        <sup>4</sup>
        <bold>-dinitrophenylimino)-hydrazono]-1, 3-dihydro-indole-2-one (P-02)</bold>
      </p>
      <p>Yield 70%, m.p. &gt;300<sup>0</sup>C Rf value 0.53, <sup>1</sup>H-NMR (1H) =N-NH d 12.82,  (4-H ) d 7.6, (2 Ar-H) N-CH<sub>2</sub> d 6.6.</p>
      <p>
        <bold>3-[(phenylimino)-hydrazono]-1,3- dihydro-indole-2-one (P-03)         </bold>
      </p>
      <p>Yield 76%,m.p.&gt;220<sup>0</sup>C,Rf value 0.46. <sup>1</sup>H-NMR (1H) =N-NH d 12.7,  (4-H) d 7.8, (4 Ar-H) d  7.3.</p>
      <p>
        <bold>3-[(2,</bold>
        <sup>4</sup>
        <bold>-dinitro-phenylimino)-hydrazono]-1,3- dihydro-indole-2-one (P-04)</bold>
      </p>
      <p>Yield  80%,m.p. &gt;290<sup>0</sup>C, Rf value 0.5. <sup>1</sup>H-NMR (1H) =N-NH d 12.15,  (4-H) d 8.5, (2 Ar-H) d  7.4.</p>
      <p>
        <bold>N-benzyl 3-<sup>(phenylimino)</sup>-5-Chloro-1,3-dihydro-indole-2-one (P-05)</bold>
      </p>
      <p>Yield 40%, m.p. &gt;300<sup>0</sup>C  Rf value 0.7.  <sup>1</sup>H-NMR (1H) =N-NH d 12.8,  (3-H) d 7.6 , (4 Ar-H) d  7.3, (2H) N-CH<sub>2</sub> d  6.6.</p>
      <p>
        <bold>3-[(phenylimino)-hydrazono]-5chloro-1,3-dihydro-indole-2-one (P-06) </bold>
      </p>
      <p>Yield 70%, m.p. &gt;300<sup>0</sup>C Rf value 0.53. <sup>1</sup>H-NMR (1H) =N-NH d 11.14,  (3-H) d 7.5 , (4 Ar-H) d  7.3.</p>
      <p>
        <bold>3-[(2,</bold>
        <sup>4</sup>
        <bold>-dinitro-phenylimino)-hydrazono]-5Chloro-1,3-dihydro-indole-2-one (P-07)</bold>
      </p>
      <p>Yield 80%, m.p. &gt;350<sup>0</sup>C Rf value 0.52. <sup>1</sup>H-NMR (1H) =N-NH d 9.4,  (3-H) d 8.3, (3 Ar-H) d  7.3.</p>
      <p>
        <bold>3-[(phenylimino)-hydrazono]-5 Fluro-1,3-dihydro-indole-2-one(P-08)</bold>
      </p>
      <p>Yield 45%, m.p. 270<sup>0</sup>C Rf value 0.9. <sup>1</sup>H-NMR (1H) =N-NH d 12.7,  (3-H) d 7.6, (4Ar-H) d  7.3.</p>
      <p>
        <bold>3-[(2,</bold>
        <sup>4</sup>
        <bold>-dinitro-phenylimino)-hydrazono]-5 Fluro-1,3-dihydro-indole-2one (P-09)</bold>
      </p>
      <p>Yield 50%, m.p. &gt;350<sup>0</sup>C Rf value 0.51. <sup>1</sup>H-NMR (1H) =N-NH d 12.7,  (3-H) d 7.6, (2Ar-H) d  7.3.</p>
      <p>
        <bold>3-[(phenylimino)-hydrazono]-5 Nitro-1,3-dihydro-indole-2-one (P-10)</bold>
      </p>
      <p>Yield 72%, m.p. 300<sup>0</sup>C Rf value 0.9.  <sup>1</sup>H-NMR (1H) =N-NH d 12.7,  (3-H) d 7.6, (2 Ar-H) d  7.3.</p>
      <p>
        <bold>3-[(2,</bold>
        <sup>4</sup>
        <bold>-dinitro-phenylimino)-hydrazono]-5 Nitro-1,3-dihydro-indole-2-one (P-11)</bold>
      </p>
      <p>Yield 80%, m.p. &gt;350<sup>0</sup>C Rf value 0.5. <sup>1</sup>H-NMR (1H) =N-NH d 9.4,  (3-H) d 8.5, (3 ArH) d  7.5.</p>
      <p>In the present study, new Schiff’s bases of        5-substituted N-benzyl isatin derivatives have been synthesized and their anti-inflammatory and analgesic activities were evaluated against standard drug. The              anti-inflammatory activity of the compounds was examined by using carrageenan induced rat paw oedema method and analgesic activity by Writhing test. The test compound P-01, P-02, P-06 and P-08 exhibit statistically significant at 3 hrs. Except P-03 .However the effect was comparable to aspirin at 3 hrs. (<xref ref-type="table" rid="idm1842156012">Table 2</xref>)</p>
      <table-wrap id="idm1842156012">
        <label>Table 2.</label>
        <caption>
          <title> Carrageenan Induced Rat Paw Oedema Method</title>
        </caption>
        <table rules="all" frame="box">
          <tbody>
            <tr>
              <td>
                <bold> </bold>
                <bold>Group</bold>
              </td>
              <td>
                <bold> </bold>
                <bold>Test Material (dose)</bold>
              </td>
              <td colspan="3">
                <bold>Mean increase in paw volume </bold>
                <bold>+</bold>
                <bold>Standard deviation and % inhibition</bold>
              </td>
            </tr>
            <tr>
              <td/>
              <td/>
              <td>0 hr.</td>
              <td>
                <bold>1 hr.</bold>
              </td>
              <td>
                <bold>3 hr.</bold>
              </td>
            </tr>
            <tr>
              <td>1.</td>
              <td>Control</td>
              <td>1.1 + 0.17</td>
              <td>1.40 + 0.12</td>
              <td>1.70 + 0.14</td>
            </tr>
            <tr>
              <td>2.</td>
              <td>Standard (Aspirin 300mg/kg)</td>
              <td>1.1 + 0.12</td>
              <td>1.3 +0.12 (33%)</td>
              <td>1.4 + 0.14 (50 %)</td>
            </tr>
            <tr>
              <td>3.</td>
              <td>P-01 (100mg/kg)</td>
              <td>1.2 + 0.12</td>
              <td>1.4 + 0.14 (33%)</td>
              <td>1.5 + 0.14 (50%)</td>
            </tr>
            <tr>
              <td>4.</td>
              <td>P-02 (100mg/kg)</td>
              <td>1.00+ 0.16</td>
              <td>1.3+ 0.16 (00%)</td>
              <td>1.5 + 0.14 (16 %)</td>
            </tr>
            <tr>
              <td>5.</td>
              <td>P-03 (100mg/kg)</td>
              <td>1.2 + 0.14</td>
              <td>1.4 + 0.14 (33%)</td>
              <td>1.4 + 0.14 (33%)</td>
            </tr>
            <tr>
              <td>6.</td>
              <td>P-06 (100mg/kg)</td>
              <td>1.1  + 0.10</td>
              <td>1.3 + 0.12 (33%)</td>
              <td>1.3 + 0.4 (33%)</td>
            </tr>
            <tr>
              <td>7.</td>
              <td>P-08 (100mg/kg)</td>
              <td>1.00 + 0.14</td>
              <td>1.2 + 0.14 (33%)</td>
              <td>1.3 + 0.17 (50%)</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The results are expressed as MEAN (+ S.D.) from six observations. One way ANOVA is followed by Dunnet’s   t- test. Group II <sup>nd</sup>to VII<sup>th</sup> is compared with group I <sup>st</sup> (control). (P&lt; 0.01); * = not significant (for 3 hrs.).    No-one compound is significant at 1 hrs (P= 0.O74). (<xref ref-type="fig" rid="idm1842134556">Figure 1</xref>) (<xref ref-type="table" rid="idm1842131316">Table 3</xref>)</p>
      <fig id="idm1842134556">
        <label>Figure 1.</label>
        <caption>
          <title> Carrageenan Induced rat paw edema</title>
        </caption>
        <graphic xlink:href="images/image18.jpg" mime-subtype="jpg"><alt-text>Figure 1. Carrageenan Induced rat paw edema</alt-text></graphic>
      </fig>
      <table-wrap id="idm1842131316">
        <label>Table 3.</label>
        <caption>
          <title> Acetic acid Induced analgesic activity</title>
        </caption>
        <table rules="all" frame="box">
          <tbody>
            <tr>
              <td>
                <bold>S.N.</bold>
              </td>
              <td>
                <bold>Group (Dose)</bold>
              </td>
              <td>
                <bold>Response time (</bold>
                <bold>+</bold>
                <bold>s.d.</bold>
                <bold>)</bold>
              </td>
              <td>
                <bold>No. of Writhing  </bold>
                <bold>   (</bold>
                <bold>+</bold>
                <bold>s.d.</bold>
                <bold>)</bold>
              </td>
              <td>
                <bold>% Inhibition</bold>
                <bold>in Writhing</bold>
              </td>
            </tr>
            <tr>
              <td>1.</td>
              <td>Control</td>
              <td>2.37 (0.33)</td>
              <td>59.83 (2.31)</td>
              <td>----------</td>
            </tr>
            <tr>
              <td>2.</td>
              <td>Standard (Aspirin 300mg/kg)</td>
              <td>5.54(0.41)</td>
              <td>15.85(2.63)</td>
              <td>73</td>
            </tr>
            <tr>
              <td>3.</td>
              <td>P-01 (100mg/kg)</td>
              <td>7.76(0.94)</td>
              <td>18.50(1.87)</td>
              <td>69</td>
            </tr>
            <tr>
              <td>4.</td>
              <td>P-02 (100mg/kg)</td>
              <td>3.13(0.33</td>
              <td>46.66(1.60)</td>
              <td>22</td>
            </tr>
            <tr>
              <td>5.</td>
              <td>P-03 (100mg/kg)</td>
              <td>4.35(0.37)</td>
              <td>35.83(1.16)</td>
              <td>40</td>
            </tr>
            <tr>
              <td>6.</td>
              <td>P-06 (100mg/kg)</td>
              <td>4.85(0.27)</td>
              <td>32.83(1.16)</td>
              <td>45</td>
            </tr>
            <tr>
              <td>7.</td>
              <td>P-08 (100mg/kg)</td>
              <td>5.42(0.60</td>
              <td>29.33(2.42)</td>
              <td>50</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The results are expressed as mean (+ S.D.) from six observations. One way ANOVA is followed by Dunnet’s   t- test. Group II <sup>nd</sup>to VII<sup>th</sup> is compared with group I <sup>st</sup> (control).(P&lt; 0.01); and are significant (<xref ref-type="fig" rid="idm1842073388">Figure 2</xref>)</p>
      <fig id="idm1842073388">
        <label>Figure 2.</label>
        <caption>
          <title> % inhibition of acetic acid induced writhing</title>
        </caption>
        <graphic xlink:href="images/image19.jpg" mime-subtype="jpg"><alt-text>Figure 2. % inhibition of acetic acid induced writhing</alt-text></graphic>
      </fig>
    </sec>
    <sec id="idm1849325060" sec-type="conclusions">
      <title>Conclusion: </title>
      <p>The experiments reported here from results of biological activity of the compounds there is a clear cut relation of compounds with each other due to structural similarity. A compound with N-benzyl-3-substituted isatin was synthesized using appropriate synthetic route and screened for analgesic and anti-inflammatory activity.The test compounds showed significant                     anti-inflammatory and analgesic activity compared with the standard drug Aspirin. The study of the   structure-activity relationship reveals that the presence of the electron withdrawing group does not affect      anti-inflammatory activity and increase in   electro-negativity increases the analgesic activity.  (<xref ref-type="table" rid="idm1842071444">Table 4</xref>)</p>
      <table-wrap id="idm1842071444">
        <label>Table 4.</label>
        <caption>
          <title> Comparative study of the activity</title>
        </caption>
        <table rules="all" frame="box">
          <tbody>
            <tr>
              <th>
                <bold>S.N.</bold>
              </th>
              <td>
                <bold>Compound</bold>
              </td>
              <td>
                <bold>R</bold>
              </td>
              <td>
                <bold>R</bold>
                <sup>
                  <bold>I</bold>
                </sup>
              </td>
              <td colspan="2">
                <bold>Activity</bold>
              </td>
            </tr>
            <tr>
              <td/>
              <td/>
              <td/>
              <td/>
              <td>
                <bold>Analgesic</bold>
              </td>
              <td>
                <bold>Anti-Inflammatory</bold>
              </td>
            </tr>
            <tr>
              <td>1</td>
              <td>P-01</td>
              <td>C<sub>6</sub>H<sub>5</sub></td>
              <td>H</td>
              <td>69</td>
              <td>50</td>
            </tr>
            <tr>
              <td>2</td>
              <td>P-02</td>
              <td>C<sub>6</sub>H<sub>4</sub>N<sub>2</sub>0<sub>2</sub></td>
              <td>H</td>
              <td>22</td>
              <td>16</td>
            </tr>
            <tr>
              <td>3</td>
              <td>P-03</td>
              <td>H</td>
              <td>H</td>
              <td>40</td>
              <td>33</td>
            </tr>
            <tr>
              <td>4</td>
              <td>P-06</td>
              <td>H</td>
              <td>Cl</td>
              <td>45</td>
              <td>33</td>
            </tr>
            <tr>
              <td>5</td>
              <td>P-08</td>
              <td>H</td>
              <td>F</td>
              <td>50</td>
              <td>50</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>This article belongs to the Public Health. The experimental data and analysis part is very sufficient, and the conclusion is very reasonable. It is              recommended to publish the article in your esteemed journal. I hope this helps.</p>
    </sec>
    <sec id="idm1849279996">
      <title>Acknowledgments</title>
      <p>This research work is completed under the supervision and guidance of Renowned Laboratory Scientist, Respected Dr. Ramesh S. Paranjape, Retired Director &amp; Scientist ‘G’ National AIDS Research Institute, India. I express my sincere gratitude towards Respected Sir for motivation and being great knowledge source for this work.</p>
    </sec>
    <sec id="idm1849280212">
      <title>Disclosures</title>
      <p>Animal ethical approval </p>
    </sec>
    <sec id="idm1849279060">
      <title>Funding</title>
      <p>None</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title> Abbreviations</title>
      <def-list>
        <def-item>
          <term>1H-NMR: Proton nuclear magnetic resonance</term>
          <def>
            <p/>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <ref id="ridm1842442716">
        <label>1.</label>
        <mixed-citation xlink:type="simple" publication-type="book">
          <name>
            <surname>Hajare</surname>
            <given-names>Rahul</given-names>
          </name>
          <name>
            <surname>Paranjape</surname>
            <given-names>Ramesh</given-names>
          </name>
          <name>
            <surname>Kulkarni</surname>
            <given-names>Smita</given-names>
          </name>
          <article-title>Tailored microwave technology for Synthesis N-[(3Z)-5-chloro-1-(morpholin-4-ylmethyl)-2-oxo-1,2-dihydro-3H-indol-3 ylidene</article-title>
          <chapter-title>pyridine-4 carbohydrazide as HIV-1 inhibitors.(2016) Drug Formulation &amp; Bioavailability Congress” September 05-07</chapter-title>
          <publisher-loc>Beijing, China</publisher-loc>
        </mixed-citation>
      </ref>
      <ref id="ridm1842439260">
        <label>2.</label>
        <mixed-citation xlink:type="simple" publication-type="book">
          <name>
            <surname>Hajare</surname>
            <given-names>Rahul</given-names>
          </name>
          <name>
            <surname>Paranjape</surname>
            <given-names>Ramesh</given-names>
          </name>
          <name>
            <surname>Kulkarni</surname>
            <given-names>Smita</given-names>
          </name>
          <article-title>Technology development and design of novel 1, 3, 5-tri substituted-1H-indole-2, 3-dione: HIV-1 Inhibitors with displays strategic nanomolar cytotoxicity</article-title>
          <date>
            <year>2016</year>
          </date>
          <chapter-title>251stACS National Meeting &amp; Exposition held on March 13-17,2016 in</chapter-title>
          <publisher-loc>San Diego, CA, USA</publisher-loc>
        </mixed-citation>
      </ref>
      <ref id="ridm1842455404">
        <label>3.</label>
        <mixed-citation xlink:type="simple" publication-type="book">
          <name>
            <surname>Hajare</surname>
            <given-names>Rahul</given-names>
          </name>
          <name>
            <surname>Kulkarni</surname>
            <given-names>Smita</given-names>
          </name>
          <name>
            <surname>Thakar</surname>
            <given-names>Madhuri</given-names>
          </name>
          <name>
            <surname>Paranjape</surname>
            <given-names>Ramesh</given-names>
          </name>
          <date>
            <year>2016</year>
          </date>
          <source>World J Pharm Pharm Sci.;</source>
          <chapter-title>Technology Development and Design of Novel 1, 3, 5-tri Substituted-1H-Indole-2, 3-Dione HIV-1 Inhibitors With Displays Strategic Nanomolar Cytotoxicity</chapter-title>
          <volume>5</volume>
          <issue>6</issue>
          <fpage>391</fpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1842553484">
        <label>4.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <article-title>Rahul Hajare, Smita Kulkarni, Madhuri Thakar, Ramesh Paranjape</article-title>
          <date>
            <year>2016</year>
          </date>
          <source>Isatin Anti-HIV Agent: A Review.Impact Factor 6.041</source>
          <volume>5</volume>
          <issue>7</issue>
          <fpage>569</fpage>
          <lpage>575</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1842298204">
        <label>5.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Srinivasan</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Muruganandan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Lal</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Chandra</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>S</surname>
            <given-names>K Tandan</given-names>
          </name>
          <name>
            <surname>V</surname>
            <given-names>R Prakash</given-names>
          </name>
          <article-title>Evaluation of anti-inflammatory activity of Pongamia pinnata leaves in rats</article-title>
          <date>
            <year>2001</year>
          </date>
          <source>Journal of Ethno pharmacology</source>
          <volume>78</volume>
          <fpage>151</fpage>
          <lpage>157</lpage>
        <pub-id pub-id-type="doi">10.1016/s0378-8741(01)00333-6</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>